来源：金融界 8月22日，东富龙今日收盘15.39元，下跌2.16%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到78.80倍，总市值117.86亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.95倍，行业中值40.49倍，东富龙排名 第99位。 截至2025年一季报，共有1家机构持仓东富龙，其中基金1家，合计持股数218.45万股，持股市值0.29亿 元。 东富龙科技集团股份有限公司的主营业务是为全球制药企业提供制药工艺、核心装备、系统工程整体解 决方案。公司的主要产品是生物工艺板块、制剂板块、工程整体解决方案板块、食品装备工程板块。 最新一期业绩显示，2025年一季报，公司实现营业收入11.37亿元，同比2.58%；净利润2013.26万元， 同比-68.87%，销售毛利率24.45%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13东富龙78.8060.721.51117.86亿行业平均 56.9554.955.11122.43亿行业中值40.4939.722.9459.69亿1九安医疗11.7111.840.92197.54亿2英科医疗 15.7917. ...

Company Overview - Dongfulong's closing price on August 7 was 14.91 yuan, with an increase of 1.15%, resulting in a rolling PE ratio of 76.35 times and a total market value of 11.418 billion yuan [1] - The company specializes in providing pharmaceutical process, core equipment, and overall engineering solutions for global pharmaceutical enterprises, with main products in the bioprocessing, formulation, engineering solutions, and food equipment sectors [1] Financial Performance - In the first quarter of 2025, Dongfulong reported operating revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, while net profit was 20.1326 million yuan, reflecting a year-on-year decrease of 68.87%, with a sales gross margin of 24.45% [1] Industry Comparison - The average PE ratio for the medical device industry is 54.79 times, with a median of 37.86 times, placing Dongfulong at the 97th position in the industry ranking [1] - The company's static PE ratio is 58.83 times, and its price-to-book ratio is 1.46 times [2] Capital Flow - On August 7, Dongfulong experienced a net inflow of main funds amounting to 3.6885 million yuan, although it has seen a total outflow of 64.1225 million yuan over the past five days [1]

Group 1 - The core viewpoint of the articles highlights Dongfulong's current market performance, with a closing price of 14.74 yuan and a PE ratio of 75.48, significantly higher than the industry average of 53.93 [1][2] - Dongfulong's total market capitalization is reported at 11.288 billion yuan, ranking 97th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of main funds amounting to 54.80 million yuan on August 6, with a total outflow of 51.73 million yuan over the past five days [1] Group 2 - Dongfulong's main business involves providing pharmaceutical companies with process engineering, core equipment, and overall system solutions, with key product segments including bioprocessing, formulation, engineering solutions, and food equipment [1] - The latest quarterly report for Q1 2025 shows Dongfulong achieved a revenue of 1.137 billion yuan, reflecting a year-on-year increase of 2.58%, while net profit decreased by 68.87% to 20.13 million yuan, with a gross margin of 24.45% [1]

Group 1 - The core business of the company is to provide pharmaceutical companies worldwide with pharmaceutical processes, core equipment, and overall system engineering solutions [1] - The company's main products include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] - As of the first quarter of 2025, the company reported revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87% [1] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 72.05, significantly higher than the industry average of 55.28 and the industry median of 38.06 [2] - The total market capitalization of the company is 10.775 billion yuan [2] - As of the first quarter of 2025, there is only one institutional holder of the company, with a total holding of 2.1845 million shares valued at 2.9 million yuan [1]

Company Overview - Dongfulong Technology Group Co., Ltd. specializes in providing pharmaceutical process, core equipment, and system engineering solutions for global pharmaceutical companies [1] - The main product segments include bioprocessing, formulation, overall engineering solutions, and food equipment engineering [1] Financial Performance - For Q1 2025, the company reported revenue of 1.137 billion yuan, representing a year-on-year increase of 2.58% [1] - The net profit for the same period was 20.1326 million yuan, showing a significant year-on-year decline of 68.87% [1] - The sales gross margin stood at 24.45% [1] Market Position - As of July 24, the closing price of Dongfulong was 13.96 yuan, with a PE ratio of 71.48, marking a new low in 139 days [1] - The total market capitalization of the company is 10.691 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 54.55, with a median of 37.54, placing Dongfulong at the 95th position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, only one institution holds shares in Dongfulong, which is a fund with a total holding of 2.1845 million shares, valued at 2.9 million yuan [1]

Company Overview - Dongfulong Technology Group Co., Ltd. specializes in providing pharmaceutical process, core equipment, and system engineering solutions for global pharmaceutical companies [1] - The main product segments include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] Financial Performance - For Q1 2025, the company reported revenue of 1.137 billion yuan, representing a year-on-year increase of 2.58% [1] - The net profit for the same period was 20.1326 million yuan, showing a significant year-on-year decline of 68.87% [1] - The gross profit margin stood at 24.45% [1] Market Position - As of July 16, the closing stock price was 13.34 yuan, with a PE ratio of 68.31, marking a new low in 71 days [1] - The total market capitalization is 10.216 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 51.87, with a median of 37.48, placing Dongfulong at the 96th position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, seven institutions hold shares in Dongfulong, with a total of 89.388 million shares valued at 1.153 billion yuan [1]

Group 1 - The core business of the company is to provide pharmaceutical process, core equipment, and overall engineering solutions for global pharmaceutical enterprises [1] - The main product segments include bioprocessing, formulation, overall engineering solutions, and food equipment engineering [1] - As of March 31, 2025, the company had 31,365 shareholders, a decrease of 2,055 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The company's latest quarterly report for Q1 2025 shows a revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87%, with a gross profit margin of 24.45% [1] - The company's current price-to-earnings (PE) ratio is 61.39, compared to the industry average of 50.97 and the industry median of 36.67, ranking 94th in the industry [2] - The total market capitalization of the company is 9.182 billion yuan [2]

Group 1 - The core viewpoint of the articles highlights Dongfulong's current stock performance, with a closing price of 12.02 yuan, an increase of 1.86%, and a rolling PE ratio of 61.55 times, which is higher than the industry average of 50.80 times [1][2] - Dongfulong's total market capitalization is reported at 9.205 billion yuan, ranking 93rd in the medical device industry based on PE ratio [1][2] - The company experienced a net inflow of main funds amounting to 2.6769 million yuan on June 3, but overall, there has been a net outflow of 97,700 yuan over the past five days [1] Group 2 - Dongfulong Technology Group Co., Ltd. specializes in providing pharmaceutical process solutions, core equipment, and system engineering solutions to global pharmaceutical companies [1] - The company's main product segments include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] - In the latest quarterly report for Q1 2025, Dongfulong achieved an operating revenue of 1.137 billion yuan, reflecting a year-on-year increase of 2.58%, while net profit was reported at 20.1326 million yuan, showing a significant year-on-year decline of 68.87% with a sales gross margin of 24.45% [1]